{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-172653","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.827827+00:00","generated_at":"2026-05-17T21:23:46.584431+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Catalyst expands Board to 7 with appointment of Dr. Daniel Curran","bullets":["Board increased from 6 to 7 members; Dr. Curran appointed effective immediately.","Curran brings 25+ years pharma experience; served as SVP at Takeda Rare Genetics (2019-2023).","Currently CEO of Timberlyne Therapeutics and Managing Partner at Mountainfield Venture Partners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-172653","json":"https://secwatch.observer/filing/0001193125-25-172653.json","markdown":"https://secwatch.observer/filing/0001193125-25-172653.md","text":"https://secwatch.observer/filing/0001193125-25-172653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525172653/0001193125-25-172653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525172653/d17349d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:23:46.584431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}